ArticleOncology letters2025
Meta-analysis of the efficacy and safety of thoracic radiotherapy for extensive-stage small cell lung cancer in the era of immunotherapy.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synergistic antitumor effects of thoracic radiotherapy (TRT) are still debated due to conflicting clinical evidence. The aim of the present meta-analysis was to evaluate the efficacy and safety of chemo-immunotherapy combined with TRT in extensive-stage small cell lung cancer (ES-SCLC). CNKI, Wanfang, VIP, Pubmed, Embase and the Cochrane library were searched for published literature on chemo-immunotherapy combined with TRT for ES-SCLC between January 1, 2018, and March 4, 2024. After screening the studies and extracting data according to the inclusion criteria, Review Manager 5.4 and Stata 15 were used to assess the risk of bias of the studies and perform a meta-analysis of the data. A total of 19 relevant prospective and retrospective clinical research articles were included, involving 1,557 patients. The results of the meta-analysis demonstrated that, in terms of efficacy, chemo-immunotherapy combined with TRT significantly improves overall survival [OS; hazard ratio (HR)=0.49; 95% confidence interval, (CI), 0.34-0.71; P<0.05] and progression-free survival (PFS; HR=0.62; 95% CI, 0.51-0.76; P<0.05) of patients with ES-SCLC. Sub-group analysis indicated that primary liver metastasis was an independent predictor of poor OS (HR=2.45; 95% CI, 1.84-3.25; P<0.05), and TRT was a favorable predictor of OS (HR=0.44; 95% CI, 0.21-0.96; P<0.05) and PFS (HR=0.59; 95% CI, 0.47-0.76; P<0.05). In terms of safety, the incidence of grade ≥3 adverse reactions in the chemo-immunotherapy/TRT combination group was significantly higher than that in the chemo-immunotherapy group (risk ratio=1.30; 95% CI, 1.02-1.66; P<0.05). The most common adverse reactions in the chemo-immunotherapy/TRT combination group were radiation pneumonitis (27%; 95% CI, 14-41%), radiation esophagitis (17%; 95% CI, 9-25%) and thrombocytopenia (9%; 95% CI, 5-14%). In conclusion, chemo-immunotherapy combined with TRT demonstrated improved survival outcomes in patients with ES-SCLC, with acceptable toxicity profiles. However, further validation through prospective clinical trials is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.